Chronic Idiopathic Urticaria Ciu Pipeline Insight

DelveInsight’s, “Chronic Idiopathic Urticaria (CIU) - Pipeline Insight, 2022,” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in Chronic Idiopathic Urticaria (CIU) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. 

Geography Covered

  • Global coverage

Chronic Idiopathic Urticaria (CIU) Understanding

Chronic Idiopathic Urticaria (CIU): Overview

Chronic Urticaria (CU) conventionally refers to recurrent wheals, on most days of the week, which occur for a period of ≥ six weeks. CU can be further divided into two different subtypes, namely, Chronic Idiopathic Urticaria (CIU) (also called chronic spontaneous urticaria) and chronic inducible urticaria (also called physical urticaria). In most patients, CU is a sporadic and self-limited disorder. Chronic spontaneous urticaria refers to chronic urticaria that has no specific cause or trigger. Weals are present on most days of the week for 6 weeks or more. Chronic spontaneous urticaria was previously referred to as Chronic Idiopathic Urticaria (CIU). This term is no longer used as many cases have an autoimmune basis.


"Chronic Idiopathic Urticaria (CIU) - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Idiopathic Urticaria (CIU) pipeline landscape is provided which includes the disease overview and Chronic Idiopathic Urticaria (CIU) treatment guidelines. The assessment part of the report embraces, in depth Chronic Idiopathic Urticaria (CIU) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Idiopathic Urticaria (CIU) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Idiopathic Urticaria (CIU) R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Idiopathic Urticaria (CIU).

Chronic Idiopathic Urticaria (CIU) Emerging Drugs Chapters

This segment of the Chronic Idiopathic Urticaria (CIU) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.


Chronic Idiopathic Urticaria (CIU) Emerging Drugs


Ligelizumab: Novartis

Ligelizumab (QGE031) is a next generation monoclonal anti-immunoglobulin E (IgE) antibody. Ligelizumab is thought to work by blocking the IgE/FcεRI pathway, a key driver of the inflammatory process in CSU. Ligelizumab (QGE031) had received FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU). Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines


Dupilumab: Regeneron

It is a human monoclonal antibody of the immunoglobulin G4 subclass that inhibits IL-4 and interleukin-13 (IL-13) signaling by specifically binding to the IL-4 receptor alpha subunit, which is shared by the IL-4 and IL-13 receptor complexes. It is in phase III stage of development to treat Chronic Spontaneous Urticaria.


Tezepelumab: Amgen

Tezepelumab is an investigational, potential first-in-class human monoclonal antibody that works on the primary source of inflammation: the airway epithelium, which is the first point of contact for viruses, allergens, pollutants and other environmental insults. Specifically, tezepelumab targets and blocks thymic stromal lymphopoietin (TSLP), a key epithelial cytokine that sits at the top of multiple inflammatory cascades and initiates an overreactive immune response to allergic, eosinophilic and other types of airway inflammation associated with severe asthma

Further product details are provided in the report……..

Chronic Idiopathic Urticaria (CIU): Therapeutic Assessment

This segment of the report provides insights about the different Chronic Idiopathic Urticaria (CIU) drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Chronic Idiopathic Urticaria (CIU)

There are approx. 20+ key companies which are developing the therapies for Chronic Idiopathic Urticaria (CIU). The companies which have their Chronic Idiopathic Urticaria (CIU) drug candidates in the most advanced stage, i.e. phase III include, Novartis.

Phases

DelveInsight’s report covers around 20+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration


Chronic Idiopathic Urticaria (CIU) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type


Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Chronic Idiopathic Urticaria (CIU): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Chronic Idiopathic Urticaria (CIU) therapeutic drugs key players involved in developing key drugs.


Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chronic Idiopathic Urticaria (CIU) drugs.

Chronic Idiopathic Urticaria (CIU) Report Insights

  • Chronic Idiopathic Urticaria (CIU) Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Chronic Idiopathic Urticaria (CIU) Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

  • How many companies are developing Chronic Idiopathic Urticaria (CIU) drugs?
  • How many Chronic Idiopathic Urticaria (CIU) drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Idiopathic Urticaria (CIU)?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Chronic Idiopathic Urticaria (CIU) therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Chronic Idiopathic Urticaria (CIU) and their status?
  • What are the key designations that have been granted to the emerging drugs?

Introduction

Executive Summary

Chronic Idiopathic Urticaria (CIU): Overview

  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management

Pipeline Therapeutics

  • Comparative Analysis

Therapeutic Assessment

  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

  • Comparative Analysis

Ligelizumab: Novartis

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

  • Comparative Analysis

Tezepelumab: Amgen

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

  • Comparative Analysis

UCB8600: UCB Pharma

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Preclinical and Discovery Stage Products

  • Comparative Analysis

Drug name: Company name

  • Product Description
  • Research and Development
  • Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

  • Comparative Analysis

Chronic Idiopathic Urticaria (CIU) Key Companies

Chronic Idiopathic Urticaria (CIU) Key Products

Chronic Idiopathic Urticaria (CIU)- Unmet Needs

Chronic Idiopathic Urticaria (CIU)- Market Drivers and Barriers

Chronic Idiopathic Urticaria (CIU)- Future Perspectives and Conclusion

Chronic Idiopathic Urticaria (CIU) Analyst Views

Chronic Idiopathic Urticaria (CIU) Key Companies

Appendix

List of Table

Table 1: Total Products for Chronic Idiopathic Urticaria (CIU)

Table 2: Late Stage Products

Table 3: Mid Stage Products

Table 4: Early Stage Products

Table 5: Pre-clinical & Discovery Stage Products

Table 6: Assessment by Product Type

Table 7: Assessment by Stage and Product Type

Table 8: Assessment by Route of Administration

Table 9: Assessment by Stage and Route of Administration

Table 10: Assessment by Molecule Type

Table 11: Assessment by Stage and Molecule Type

Table 12: Inactive Products

List of Figures

Figure 1: Total Products for Chronic Idiopathic Urticaria (CIU)

Figure 2: Late Stage Products                             

Figure 3: Mid Stage Products

Figure 4: Early Stage Products

Figure 5: Preclinical and Discovery Stage Products

Figure 6: Assessment by Product Type

Figure 7: Assessment by Stage and Product Type

Figure 8: Assessment by Route of Administration

Figure 9: Assessment by Stage and Route of Administration

Figure 10: Assessment by Molecule Type

Figure 11: Assessment by Stage and Molecule Type

Figure 12: Inactive Products   

• Novartis

• Regeneron

• Amgen

• AstraZeneca

• United BioPharma

• Celltrion

• Celldex Therapeutics

• CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

• Gilead Sciences

• Stero Biotechs Ltd.

• UCB Biopharma SRL

• GlaxoSmithKline

• UBP Greater China (Shanghai) Co., Ltd

• Genentech

• Kiniksa Pharmaceuticals, Ltd.

Forward to Friend

Need A Quote